Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases.

NCT05273489 | Completed

• 1 other identifier: CRLM1
• Study Type: observational
• Target: 170
• Locations: 0 countries
• Sites: N/A

Brief Summary

Retrospective analysis of a prospectively collected database of 170 patients between 2004 and 2020, who underwent liver resections for CRLM (colorectal liver metastases) at The Queen Elizabeth Hospital trying to determine rates and patterns of recurrence following liver resections for CRLM and concurrently, characterise clinical, pathological and treatment-related factors that could function as predictors of recurrence or survival, particularly neoadjuvant chemotherapy and tumour clearance.

Conditions

Colorectal Cancer Metastatic; Liver Metastases

Outcome Measures

Primary Outcomes (2)

• Recurrence

  Recurrence rate

  From surgery to recurrence, up to 16 years

• Survival

  up to16 years

  From surgery to death or end of the study, up to 16 years

Secondary Outcomes (2)

• Resection margins

  From surgery to death or end of the study, up to 16 years

• Neoadjuvant Chemotherapy

  From surgery to death or end of the study, up to 16 years

Interventions

Hepatectomy PROCEDURE

Neoadjuvant treatment

Also known as: Chemotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Australian citizens (most of them locals) treated at The Queen Elizabeth Hospital, Adelaide, SA.

You may qualify if:

• Patients who underwent a liver resection for CRLM at The Queen Elizabeth Hospital between December 2004 to September 2020

You may not qualify if:

• Patients whose procedures were abandoned due to unresectable tumour burden

Sponsors & Collaborators

• Hospital Maciel: lead
• University of Adelaide: collaborator

MeSH Terms

Interventions

Hepatectomy; Drug Therapy

Intervention Hierarchy (Ancestors)

Digestive System Surgical Procedures; Surgical Procedures, Operative; Therapeutics

Study Officials

• Mauro A Perdomo, MD, MHA

  Assitant Professor at Clinica Quirurgica 3. Universidad de la Republica. Monteviedo, Uruguay

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, General Surgeon

Study Record Dates

• First Submitted: February 24, 2022
• First Posted: March 10, 2022
• Study Start: January 1, 2004
• Primary Completion: December 31, 2020
• Study Completion: October 31, 2021
• Last Updated: March 10, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share